- Target disease: Chagas
- Main partners (since project start): Daiichi Sankyo, Japan
- Project start: 2017
- Funding (since project start): Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Global Health Innovative Technology (GHIT) Fund, Japan; Swiss Agency for Development and Cooperation (SDC), Switzerland.
In February 2016, Daiichi Sankyo and DNDi launched a High-Throughput Screening project of 40,000 compounds from Daiichi Sankyo with the goal of discovering anti-leishmaniasis and anti-Chagas disease compounds, identifying three compound series.
The project milestone was reached with the identification of a progressable Chagas lead series with proven in vivo efficacy. Daiichi Sankyo and DNDi are now looking for funding to progress this promising series for Chagas disease in 2019.
Three T. cruzi active series with marginal activity against Leishmania were identified from a high-throughput screening of 40,000 members of the Daiichi Sankyo Pharma Space Library. Current medicinal chemistry efforts of this hit-to-lead collaboration focus on one series that was confirmed as the most promising chemotype in terms of activity and selectivity profile. To date, over 100 analogs to this series have been synthesized and tested for T. cruzi and Leishmania activities at Institut Pasteur Korea, leading to the identification of four preferred molecules nominated to proceed with pharmacokinetics studies. This project was initiated in April 2017 for a duration of 18 months.
Last update: February 2019